DermatologyInvestigational

SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate)

Topical

Overview

SYN-AKE is a synthetic dipeptide derivative inspired by the venom peptide waglerin-1 from the Temple viper. It acts as a competitive antagonist at nicotinic acetylcholine receptors on the postsynaptic muscle membrane, thereby reducing muscle contraction and potentially smoothing expression lines.

Mechanism of Action

The compound is marketed as a topical alternative to botulinum toxin, though with substantially lower receptor affinity and clinical effect..

Research Summary & Key Findings

In vitro receptor binding assays have confirmed weak antagonism at muscle-type nicotinic receptors. Small-scale cosmetic trials have suggested modest reductions in forehead and crow's feet wrinkle depth after four weeks of topical application, though blinding and placebo controls are often not rigorously detailed. No studies in peer-reviewed dermatology or pharmacology journals have established standardized clinical efficacy.

Clinical Status

Investigational

SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Topical

Related Peptides in Dermatology

Find a Provider

Find a verified provider who offers SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.